PROJECT STAGE
Preclinical Development
Lead Optimisation
Lead Generation
Early Discovery
Therapeutic area Inflammation
Background info
Indication
Advantages
Intellectual property
Owner/lead

Project Aim

To develop small molecule inhibitors of MIF for the treatment of inflammatory diseases

Advantage

Lead series with more desirable chemical properties than those previously disclosed from competitor MIF programmes

Target Class

Inflammatory Cytokine

Modality

Small molecule

Current Status

Lead optimisation with in-vivo proof of concept planned

Intellectual Property

Opportunity to create a protective IPR portfolio

Offering

Licence

Key Contact

Derek Sheader
Senior Business Development Manager
  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email dataprivacy@lifearc.org.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities